期刊
BIOMATERIALS
卷 34, 期 4, 页码 1255-1260出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.biomaterials.2012.09.064
关键词
Cancer; Nanomedicine; Active targeting; Micelle; Nanobody; EGFR
资金
- MediTrans
- European Commission
- NWO-CW/STW [790.36.110, 10154]
- ZonMw [93611001]
- GACR [P-301/11/0325]
- DFG [LA-2937/1-1]
- EC [COST-Action TD1004]
Various different passively and actively targeted nanomedicines have been designed and evaluated over the years, in particular for the treatment of cancer. Reasoning that the potential of ligand-modified nanomedicines can be substantially improved if intrinsically active targeting moieties are used, we have here set out to assess the in vivo efficacy of nanobody-modified core-crosslinked polymeric micelles containing covalently entrapped doxorubicin. Nanobody-modified polymeric micelles were found to inhibit tumor growth even in the absence of a drug, and nanobody-modified micelles containing doxorubicin were significantly more effective than nanobody-free micelles containing doxorubicin. Based on these findings, we propose that the combination of two therapeutic strategies within one nano-medicine formulation, i.e. the intrinsic pharmacological activity of ligand-modified carrier materials with the cytostatic activity of the incorporated chemotherapeutic agents, is a highly promising approach for improving the efficacy of tumor-targeted combination therapy. (C) 2012 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据